The World Health Organization will begin with the use of a second experimental vaccine against Ebola in the Democratic Republic of the Congo to halt efforts to stem the growing outbreak and among critics of MSF until now
Since the outbreak in August became known , more than 200,000 people have received doses of the vaccine produced by Merck, which will continue to be used in the Democratic Republic of the Congo. The second vaccine manufactured by Johnson & Johnson will be used in areas where Ebola is not actively expanding from October onwards, said the United Nations Department of Health.
MSF, for their part, asked that an independent committee administer vaccinations to increase transparency and improve access to medicines.
The medical charity accuses the WHO of "limiting the availability of vaccines on-site" and limiting the selection criteria of the dose.